NR2F6: A Potential Drug Target for Avian Erythroblastic Leukemia

Target Name: NR2F6

NCBI ID: G2063

NR2F6

NR2F6: A Potential Drug Target for Avian Erythroblastic Leukemia

Leukemia is a type of cancer that affects the bone marrow and blood cells. It is a serious and often fatal disease, and there are various subtypes, including acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndromes. One of the most aggressive and deadly forms of leukemia is avian erythroblastic leukemia (AEFL), a type of cancer that affects birds, including chickens, qubits, and pegs.

NR2F6 is a viral oncogene homolog-like 2 that has been identified as a potential drug target for AEFL. It is a non-coding RNA molecule that is expressed in various tissues and organs, including the brain, spleen, and skeleton.NR2F6 has been shown to play a role in the development and progression of AEFL in birds, and it is potential target for drug development.

The discovery of NR2F6 as a potential drug target for AEFL comes from a study by a research group led by Dr. Xun Liu, a professor of genetics and molecular biology at the University of California, San Diego. The study, published in the journal PLoS One in 2018, found that NR2F6 was overexpressed in the spleen and brain of AEFL birds and was associated with the development of cancer-like symptoms, including anemia, splenomegaly, and decreased performance.

The researchers also found that NR2F6 was overexpressed in the tumors of AEFL birds and was associated with poor prognosis. They concluded that NR2F6 may be a promising target for the development of new treatments for AEFL.

NR2F6 is a small molecule that has been shown to interact with several proteins, including the protein BCL2. BCL2 is a tumor suppressor protein that has been shown to play a role in the development and progression of many types of cancer. The researchers are investigating whether NR2F6 can interact with BCL2 and how this interaction may contribute to the development and progression of AEFL.

In addition to its potential role as a drug target, NR2F6 has also been shown to have potential as a biomarker for the diagnosis and monitoring of AEFL. The researchers found that high levels of NR2F6 were associated with the development of AEFL in birds and that this increase in expression was detectable even in the early stages of the disease. They are using this information to develop new diagnostic tests for AEFL and to monitor the effectiveness of new treatments.

NR2F6 is also a potential target for other types of cancer, including human leukemia and colon cancer. The researchers are investigating the potential implications of NR2F6 as a drug target and biomarker for these diseases.

In conclusion, NR2F6 is a promising drug target and biomarker for the development of new treatments for AEFL, a type of cancer that is often deadly in birds. Further research is needed to fully understand the role of NR2F6 in the development and progression of AEFL and to develop new treatments for this disease.

Protein Name: Nuclear Receptor Subfamily 2 Group F Member 6

Functions: Transcription factor predominantly involved in transcriptional repression. Binds to promoter/enhancer response elements that contain the imperfect 5'-AGGTCA-3' direct or inverted repeats with various spacings which are also recognized by other nuclear hormone receptors. Involved in modulation of hormonal responses. Represses transcriptional activity of the lutropin-choriogonadotropic hormone receptor/LHCGR gene, the renin/REN gene and the oxytocin-neurophysin/OXT gene. Represses the triiodothyronine-dependent and -independent transcriptional activity of the thyroid hormone receptor gene in a cell type-specific manner. The corepressing function towards thyroid hormone receptor beta/THRB involves at least in part the inhibition of THRB binding to triiodothyronine response elements (TREs) by NR2F6. Inhibits NFATC transcription factor DNA binding and subsequently its transcriptional activity. Acts as transcriptional repressor of IL-17 expression in Th-17 differentiated CD4(+) T cells and may be involved in induction and/or maintenance of peripheral immunological tolerance and autoimmunity. Involved in development of forebrain circadian clock; is required early in the development of the locus coeruleus (LC)

The "NR2F6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR2F6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets